arrow
Y

Yann Touchefeu

institut des maladies de l'appareil digestif
H指数:29
被引数:3,398

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma

Child-Pugh B肝细胞癌患者对阿替利珠单抗-贝伐珠单抗反应的临床预测因子

2026-06-110
OAAI
Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients

钇-90玻璃微球选择性内部放疗治疗肝细胞癌的有效性与安全性:来自多中心前瞻性PROACTIF队列的989例真实世界结果

2026-04-170
OAAI
The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab

“A-B-C”分类揭示了atezolizumab/bevacizumab治疗下肝细胞癌患者的结局轨迹

2025-11-250
OAAI
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study

微卫星不稳定/错配修复缺陷型胆道癌中免疫检查点抑制剂的实时世界疗效:一项AGEO研究

2025-07-300
PRE
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

瑞戈非尼联合改良吉西他滨-奥沙利铂方案治疗晚期胆道癌。BREGO研究(随机 Ib/II 期)。

2025-06-010
OAAI
Lack of prior screening for advanced liver fibrosis in patients with newly diagnosed hepatocellular carcinoma: Results from a prospective multicentre study

对 newly diagnosed hepatocellular carcinoma 患者未进行高级别肝纤维化前期筛查:一项前瞻性多中心研究的结果

2025-04-300
PRE
Mixed neuroendocrine non-neuroendocrine neoplasm combining neuroendocrine tumor with hepatocellular carcinoma in the context of multiple endocrine neoplasia type 1

混合神经内分泌-非神经内分泌新生物,在多发性内分泌腺瘤病1型的背景下,结合神经内分泌瘤与肝细胞癌。

2025-02-011
PRE
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
2024-11-121
OA
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
2024-11-010
OAAI
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
2024-09-014
OAAI
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study

三联化疗加或不加贝伐单抗作为转移性结直肠癌的一线治疗: 一项AGEO多中心真实世界研究

2024-09-010
PRE
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
2023-04-013
OAAI
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
2022-10-0120
OAAI